Article
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Sept 2013
Yang James Chih-Hsin, Hirsh Vera, Schuler Martin, Yamamoto Nobuyuki, O'Byrne Kenneth J, Mok Tony S K, Zazulina Victoria, Shahidi Mehdi, Lungershausen Juliane, Massey Dan, Palmer Michael, Sequist Lecia V
Abstract excerpt
PURPOSE: Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed. PATIENTS AND METHODS: Three hundred forty-five patients with advanced epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma were randomly assigned 2:1 to afatinib 40 mg per day or up to six cycles of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.